pulmonary tuberculosis
Conditions
Interventions
real-world cohort:None
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
12 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Real World Cohort: (1) Aged >=12 years, both sexes. (2) Patient with clinically diagnosed or bacteriologically confirmed pulmonary tuberculosis (TB) who received TB treatment; (3) Any diagnostic field contains "keywords related to tuberculosis diagnosis (pulmonary tuberculosis, tracheal tuberculosis, pleural tuberculosis, tuberculous pleurisy, hematogenous disseminated tuberculosis, miliary tuberculosis)", or the diagnostic code contains "ICD codes related to pulmonary tuberculosis and their diagnostic names (1B10.0 Respiratory tuberculosis, confirmed; 1B10.1 Respiratory tuberculosis, unconfirmed; 1B10.Z Respiratory tuberculosis, not specified as bacteriologically or histologically confirmed; 1B13.0&XA57M6 Acute miliary tuberculosis of a single specified site, lung; 1B13.1&XA57M6 Acute miliary tuberculosis of multiple sites, lung; 1B13.2 Acute miliary tuberculosis, unspecified site; 1B13.Z Miliary tuberculosis, unspecified)" for the patient. (4) Initiation of TB treatment on or after January 1, 2021; (5) Complete key diagnosis and treatment data available in the electronic medical record system. 2.Prospective Cohort: (1) Patient with clinically diagnosed or bacteriologically confirmed pulmonary tuberculosis (TB) who is planning to start TB treatment; (2) Voluntary participation with signed informed consent form (for adults >=18 years); parental / guardian consent and co-signed informed consent form are required for minors aged <= 18 years.
Exclusion criteria
Exclusion criteria: 1. Co-morbidity confounding: the presence of other active, life-threatening disease (e.g. late-stage malignancy, non-HIV severe immunodeficiency) for which the expected survival or priority of treatment may substantially interfere with the attribution of TB treatment outcomes; 2. Extremely poor treatment adherence: documented evidence indicating that the patient either never initiated treatment or was permanently lost to follow-up within the early treatment period (<2 weeks), precluding the collection of any valid outcome data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Predictive Performance of the model, the Area Under the Receiver Operating Characteristic curve (AUROC) ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Calibration and Reliability of the Model;Sensitivity, specificity, positive predictive value, and negative predictive value; | — |
Countries
China
Contacts
Public ContactWenhong Zhang
Huashan Hospital, Fudan University
Outcome results
None listed